Long-term clinical responses of neoadjuvant dendritic cell infusions and radiation in soft tissue sarcoma

Sarcoma

Volumn 2015, Issue , 2015, Pages

  Raj, Shailaja ^a   Bui, Marilyn M ^a   Springett, Gregory ^a   Conley, Anthony ^b   Lavilla Alonso, Sergio ^c   Zhao, Xiuhua ^a   Chen, Dungsa ^a   Haysek, Randy ^a   Gonzalez, Ricardo ^a   Letson, G Douglas ^a   Finkelstein, Steven Eric ^d   Chiappori, Alberto A ^a   Gabrilovitch, Dmitry I ^c   Antonia, Scott J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c WISTAR INSTITUTE   (United States)

^d 21ST CENTURY ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; BACKACHE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CORRELATIONAL STUDY; DENDRITIC CELL; DISTANT METASTASIS; ERYTHEMA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERPIGMENTATION; HYPERSENSITIVITY; IMMUNE RESPONSE; INJECTION SITE REACTION; MALE; MIDDLE AGED; NAUSEA; OUTCOME ASSESSMENT; PAIN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RADIATION DOSE; RASH; SKIN BRUISING; SOFT TISSUE SARCOMA; TREATMENT RESPONSE; VERY ELDERLY;

EID: 84956875433     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2015/614736     Document Type: Article

References (24)

1. A. I. Spira and D. S. Ettinger, "The use of chemotherapy in softtissue sarcomas," The Oncologist, vol. 7, no. 4, pp. 348-359, 2002.
2. M. F. Brennan, E. S. Casper, L. B. Harrison, M. H. Shiu, J. Gaynor, and S. I. Hajdu, "The role of multimodality therapy in soft-tissue sarcoma," Annals of Surgery, vol. 214, no. 3, pp. 328-336, 1991.
3. S. A. Rosenberg, J. Tepper, E. Glatstein et al., "The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy," Annals of Surgery, vol. 196, no. 3, pp. 305-315, 1982.
4. P. W. Pisters, L. B. Harrison, D. H. Leung, J. M. Woodruff, E. S. Casper, and M. F. Brennan, "Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma," Journal of Clinical Oncology, vol. 14, no. 3, pp. 859-868, 1996.
5. B. Rooser, P. Gustafson, and A. Rydholm, "Is there no influence of local control on the rate of metastases in high-grade soft tissue sarcoma?" Cancer, vol. 65, no. 8, pp. 1727-1729, 1990.
6. J.-M. Coindre, P. Terrier, L. Guillou et al., "Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas," Cancer, vol. 91, no. 10, pp. 1914-1926, 2001.
7. J. F. Tierney, "Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data," The Lancet, vol. 350, no. 9092, pp. 1647-1654, 1997.
8. S. Frustaci, F. Gherlinzoni, A. De Paoli et al., "Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial," Journal of Clinical Oncology, vol. 19, no. 5, pp. 1238-1247, 2001.
9. D. Nelson, S. Fisher, and B. Robinson, "The trojan Horse approach to tumor immunotherapy: targeting the tumor microenvironment," Journal of Immunology Research, vol. 2014, Article ID 789069, 14 pages, 2014.
10. J. Banchereau and R. M. Steinman, "Dendritic cells and the control of immunity," Nature, vol. 392, no. 6673, pp. 245-252, 1998.
11. G. Schreibelt, J. Tel, K. H. E. W. J. Sliepen et al., "Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy," Cancer Immunology, Immunotherapy, vol. 59, no. 10, pp. 1573-1582, 2010.
12. S. E. Finkelstein, C. Iclozan, M. M. Bui et al., "Combination of external beamradiotherapy (EBRT)with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients," International Journal of Radiation Oncology, Biology, Physics, vol. 82, no. 2, pp. 924-932, 2012.
13. M. Chakraborty, S. I. Abrams, C. N. Coleman, K. Camphausen, J. Schlom, and J. W. Hodge, "External beamradiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing," Cancer Research, vol. 64, no. 12, pp. 4328-4337, 2004.
14. B. Park, C. Yee, and K.-M. Lee, "The effect of radiation on the immune response to cancers," International Journal ofMolecular Sciences, vol. 15, no. 1, pp. 927-943, 2014.
15. E. Nikitina and D. I. Gabrilovich, "Combination of γ-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer," International Journal of Cancer, vol. 94, no. 6, pp. 825-833, 2001.
16. S. Teitz-Tennenbaum, Q. Li, S. Rynkiewicz et al., "Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration," Cancer Research, vol. 63, no. 23, pp. 8466-8475, 2003.
17. S. Rusakiewicz, M. Semeraro, M. Sarabi et al., "Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors," Cancer Research, vol. 73, no. 12, pp. 3499-3510, 2013.
18. P. Brinkrolf, S. Landmeier, B. Altvater et al., "A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease," International Journal of Cancer, vol. 125, no. 4, pp. 879-886, 2009.
19. D. Berghuis, S. J. Santos, H. J. Baelde et al., "Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T-lymphocyte infiltration and affect tumour progression," The Journal of Pathology, vol. 223, no. 3, pp. 347-357, 2011.
20. V. Pisarev, B. Yu, R. Salup, S. Sherman, D. C. Altieri, and D. I. Gabrilovich, "Full-length dominant-negative survivin for cancer immunotherapy," Clinical Cancer Research, vol. 9, no. 17, pp. 6523-6533, 2003.
21. D. C. Altieri, "Validating survivin as a cancer therapeutic target," Nature Reviews Cancer, vol. 3, no. 1, pp. 46-54, 2003.
22. J. D. Geiger, R. J. Hutchinson, L. F. Hohenkirk et al., "Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression," Cancer Research, vol. 61, no. 23, pp. 8513-8519, 2001.
23. S. E. Finkelstein, T. Carey, I. Fricke et al., "Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer andmelanoma," Journal of Immunotherapy, vol. 33, no. 8, pp. 817-827, 2010.
24. W. J. Lesterhuis, I. J. M. De Vries, G. Schreibelt et al., "Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients," Clinical Cancer Research, vol. 17, no. 17, pp. 5725-5735, 2011.